Agenus Inc. Reports Q3 2025 Achievements: Regulatory Progress, New Data Revelations, and AI-Driven Collaborations’
LEXINGTON, Mass. Agenus Inc. (Nasdaq: AGEN) has announced its financial results for the third quarter of 2025, showcasing significant clinical and regulatory advancements. These developments reflect the company’s commitment to innovative solutions in the field of immuno-oncology.
Compassionate Access in France’
One of the major highlights from this quarter is the government-funded, reimbursed compassionate access (Accès Compassionnel - AAC) for Agenus’ investigational combination therapy of botensilimab and balstilimab (BOT/BAL) in France. This regimen targets patients with refractory metastatic colorectal cancer (CRC) that is stable to microsatellites (MSS). This pivotal decision by the French Agency for the Safety of Health Products (ANSM) allows eligible patients with limited treatment options access to this promising IO combination. The AAC approval underscores the potential of BOT/BAL in addressing unmet medical needs in challenging cancer types.
New Clinical Trial and Data Insights’
Agenus also initiated the global Phase 3 BATTMAN trial, marking a significant step in the clinical development of BOT/BAL. This international study aims to assess the efficacy and safety of the combination treatment across various challenging cancer types. The company presented new survival data at the European Society for Medical Oncology (ESMO) and its Gastrointestinal Congress (ESMOGI), covering more than 400 patients across five refractory cancer types. These preliminary results signal potential for BOT/BAL in extending survival in heavily pre-treated cancer populations.
AI Collaboration for Predictive Biomarkers’
In an ambitious stride towards precision medicine, Agenus entered a research collaboration with Noetik, an AI-driven leader in spatial and multimodal biology. This partnership aims to leverage Noetik’s proprietary virtual cell foundation models to develop predictive biomarkers of response to BOT/BAL. By integrating advanced AI technology, the collaboration seeks to enhance patient stratification and optimize therapeutic outcomes in clinical settings.
Conclusion’
Agenus’ third-quarter achievements illustrate a multi-faceted approach to advancing cancer treatment ranging from regulatory progress in Europe to global clinical collaborations. The integration of AI to refine therapeutic strategies marks a forward-thinking approach, cementing the company’s position as a leader in the immuno-oncology landscape.
Comments